Strategic Pivot in Oncology: Context Therapeutics Axes CT-95 Program to Preserve Cash and Double Down on Pipeline Assets CTIM-76 and CT-202
Executive Overview In a decisive move emblematic of the hyper-selective, risk-averse climate currently dominating the biotech sector, Philadelphia-based Context Therapeutics...
